Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
University of Heidelberg Medical Center
Pfizer
Astex Pharmaceuticals, Inc.
Kyowa Kirin Co., Ltd.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
Baylor College of Medicine
M.D. Anderson Cancer Center
Seagen Inc.
Seagen Inc.
AVEO Pharmaceuticals, Inc.
Washington University School of Medicine